

Haematologica
HAEMATOL/2019/240564
Version 3

The role of 18F-FDG-PET in detecting Richter's transformation of chronic lymphocytic leukemia in patients receiving therapy with a B-cell receptor inhibitor

Yucai Wang, Kari G. Rabe, Michael S. Bold, Min Shi, Curtis A. Hanson, Susan M. Schwager, Timothy G. Call, Saad S. Kenderian, Eli Muchtar, Suzanne R. Hayman, Amber B. Koehler, Amie L. Fonder, Asher A. Chanan-Khan, Daniel L. Van Dyke, Susan L. Slager, Neil E. Kay, Wei Ding, Jose F. Leis, and Sameer A. Parikh

Disclosures: SSK acknowledges consultancy with LeahLabs, and Torque; grants/pending grants (to the institution) from Novartis, Kite, Gilead, MorphoSys, Tolero, Humanigen, Lentigen, Actinium, Celgene, and Juno; patents (planned, pending, or issued) with Novartis and Humanigen; royalties with Novartis and Humanigen; scientific advisory board with Humanigen. NEK acknowledges grants/pending grants (to the institution) from Acerta Pharma, MEI Pharma, Pharmacyclics, and Tolero; board membership in the data and safety monitoring committee capacity for Agios, Celgene, Cytomx, Infinity, MorphoSys and in the Advisory Board capacity for Acerta, AstraZeneca, Cytomx, Dava, Juno, Pharmacyclics, and Tolero. WD acknowledges grants/pending grants (to the institution) from Merck; and consultancy in an Advisory Board capacity for Merck, Octapharma and Alexion. SAP acknowledges grants/pending grants (to the institution) from Pharmacyclics, MorphoSys, Janssen, AstraZeneca, TG Therapeutics, and Ascentage Pharma; and participation in Advisory Board meetings of Pharmacyclics, AstraZeneca, Genentech, Gilead, and AbbVie (not personally compensated). All other authors reported no disclosures.

Contributions: YW and SAP designed the study. YW, KGR, MSB, MS, CAH, and SMS collected data. KGR, YW, and SAP analyzed and interpreted data. YW wrote the first draft of the manuscript. All authors reviewed and revised the manuscript.